Business Wire

NY-CLARITY-AI

2.8.2022 14:02:12 CEST | Business Wire | Press release

Share
Clarity AI Named a Leader in ESG Ratings, Data, And Analytics Report by Independent Research Firm

Clarity AI announced today that they have been named a leader in “The Forrester New Wave™: ESG Ratings, Data, And Analytics, Q3 2022.” Clarity AI received a differentiated rating, the highest score possible across 7 of the 10 criteria evaluated: Analytics Capabilities, Standards Integrity, Presentation, Connections/Integrations, Execution Roadmap, Market Approach, and Product Vision.

“We are thrilled to be included in this report, and we thank our clients for making themselves available to Forrester for open, transparent discussions about Clarity AI and our product and strategy,” said Angel Agudo, VP of Product and Member of the Board at Clarity AI. “We believe we are bringing the very best product to market, and to see us land in the Leader section of this report is both validating and humbling for us.”

Forrester’s take on Clarity AI includes the following:

  • Offers strong analytics and user presentation capabilities. Clarity AI makes it easy for users to assess individual companies’ ESG-driven impact and benchmark it against peers (to support EU taxonomy-aligned reporting, for example). The web application is particularly well-designed and easy for users to navigate and explore.”
  • Is the best fit for companies that need to manage lots of ESG data. Many of Clarity AI’s financial services clients use it to model ESG data from a huge universe of companies and financial instruments in order to create and test new products and optimize portfolios.”

Additionally, Clarity AI clients, whom the analyst team at Forrester interviewed, had the following to say:

  • “They understood nuances that their competitors didn’t even know existed.”
  • “It’s very easy to see a company’s alignment with technical standards.”
  • “The process of connecting was seamless; it took only a month to get the API set up properly.”

A total of nine providers were evaluated in “The Forrester New Wave™: ESG Ratings, Data, And Analytics” report. Among the nine, the Forrester report cites that Clarity AI has the highest strategy score.

Mr. Agudo adds, “Forrester’s analysis provides a good view into the Clarity AI product vision and strategy that extends to our entire offering, which includes solutions and capabilities to cover Impact assessment, ESG risk assessment, carbon foot-printing, investment portfolio analysis, and the regulatory requirements, including associated reporting needs , associated with EU Taxonomy, SFDR and MiFID II, as well as the Paris Agreement (i.e., Net Zero) and the TCFD framework.”

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, companies, governments, and consumers. As of July 2022, Clarity AI’s platform analyzes more than 50,000 companies, 300,000 funds, 198 countries and 188 local governments – 2-3 times more than any other player in the market – and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its client network manages tens of trillions in assets under management. clarity.ai

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye